ViraTherapeutics starts second oncolytic virus development program with German major

5 March 2018

Austrian biotech firm ViraTherapeutics today announced the expansion of its current collaboration with German family-owned pharma major Boehringer Ingelheim, with a second oncolytic virus program.

The new development program is an oncolytic virus, stemming from ViraTherapeutics' technology platform. The vesicular stomatitis virus (VSV) will be armed with an additional immunotherapeutic component from Boehringer Ingelheim. Boehringer Ingelheim has agreed to cover all research and development costs for the program. Further financial details were not disclosed.

Under the terms of the deal signed between the companies in 2016, which could be worth up to 210 million euros ($258.5 million), Boehringer Ingelheim received the right to acquire ViraTherapeutics after conclusion of Phase I clinical development.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK